Analyst Price Targets — CRMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 28, 2026 11:41 am | Leonid Timashev | RBC Capital | $14.00 | $7.82 | TheFly | CorMedix price target raised to $14 from $13 at RBC Capital |
| March 6, 2026 8:13 pm | Roanna Ruiz | Leerink Partners | $13.00 | $6.46 | StreetInsider | CorMedix (CRMD) PT Lowered to $13 at Leerink Partners |
| January 23, 2026 11:08 am | — | H.C. Wainwright | $13.00 | $7.44 | TheFly | CorMedix price target lowered to $13 from $18 at H.C. Wainwright |
| January 21, 2026 11:34 am | — | RBC Capital | $13.00 | $6.88 | TheFly | CorMedix price target lowered to $13 from $22 at RBC Capital |
| January 8, 2026 5:42 pm | — | Truist Financial | $16.00 | $7.44 | TheFly | CorMedix price target lowered to $16 from $20 at Truist |
| October 21, 2025 11:08 am | Gregory Renza | RBC Capital | $22.00 | $12.16 | TheFly | CorMedix price target raised to $22 from $21 at RBC Capital |
| August 8, 2025 10:03 am | Brandon Folkes | H.C. Wainwright | $17.00 | $10.33 | TheFly | CorMedix price target lowered to $17 from $20 at H.C. Wainwright |
| March 13, 2024 6:21 am | Gregory Renza | RBC Capital | $9.00 | $3.90 | StreetInsider | CorMedix (CRMD) PT Lowered to $9 at RBC Capital |
Latest News for CRMD
PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference being held in Boston on…
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.
CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRMD.
U.S. House Trading
No House trades found for CRMD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.